CellProthera collaborates with Japanese stem cell experts at Shonan-Kamakura General Hospital (SKGH) on clinical manufacturing for upcoming autologous stem cell trials in ischemic diseases
A 20 year old promise slowly becoming a reality
Kim Smith, a 66-year-old heart attack patient, experienced a life-changing breaktrough after receiving stem cell therapy at Queen Elizabeth Hospital Birmingham (QEHB)
Final patient receives ProtheraCytes(R) cell therapy to regenerate damaged heart tissue following severe heart attack. Study remains on track for final readout in H1 2024
DDW’s Reece Armstrong speaks to Hendrik Streefkerk, Chief Medical Officer and Drug Safety Officer of CellProthera about the company’s cell therapy for acute myocardial infarction (AMI) and why regenerative medicine could be key to treating cardiac diseases.
Peter Altman, CEO of BioCardia, and Matthieu de Kalbermatten, CEO of CellProthera, comment on trans-endocardial intramyocardial delivery systems for biotherapeutics to treat heart failure, ischemia, and infarction, and the importance of the right delivery solution.
"Cell-based therapies have the potential to regenerate heart tissue as an alternative to heart transplante. Here, Dr Ibon GARITAONANDIA, Chief Scientific Officer at CellProthera, shares how CD34+ cells are demonstrating promising results in clinical studies."
"Autologous cell therapies are made from living cells, harvested from specific people. Every batch of inputs is different which makes predicting how each will perform in manufacturing a major challenge.Indeed, for Matthieu de Kalbermatten, CEO of France-based cell therapy developer CellProthera, starting material variability is the major issue facing the industry."
" BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients"
"Through its Phase I/IIb EXCELLENT clinical trial, CellProthera, a France-based biotechnology research company focusing on cardiac tissue regeneration, is demonstrating the safety and efficacy of a cell therapy approach to regenerating tissue following myocardial infarction. Here, CEO Matthieu de Kalbermatten shares his ambition to fulfil the promise of stem cell research"...